New inhaled therapy aims to improve breathing in COPD patients
NCT ID NCT07658339
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests whether an inhaled medication called HSK39004 can improve lung function in people with moderate to severe chronic obstructive pulmonary disease (COPD). Participants receive either the drug or a placebo twice daily for 24 weeks. The main goal is to measure changes in how much air they can exhale in one second over a 12-hour period.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HSK39004 inhalation suspension
- What this could lead to
- If successful, this could provide a new inhaled treatment option to help people with COPD breathe more easily and maintain better lung function.
- What could go wrong
- This is a phase 3 trial, but results may not show meaningful improvement over placebo. Side effects or lack of long-term benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could remote rehab keep COPD patients out of the hospital?
- Chest vibrations may boost lung sample collection
- Sports-Inspired balance training could help COPD patients avoid falls
- Can remote care tame COPD Flare-Ups?
- Can a biologic clear the clogged airways of COPD?
- Can animated videos boost Self-Care in lung disease better than paper brochures?